Premium
Mirabegron the first β 3 ‐adrenoceptor agonist for overactive bladder ( OAB ): a summary of the phase III studies
Author(s) -
Chapple Christopher
Publication year - 2014
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12773
Subject(s) - mirabegron , tolterodine , overactive bladder , placebo , medicine , tolerability , discontinuation , urology , agonist , pharmacology , adverse effect , receptor , alternative medicine , pathology